<DOC>
	<DOCNO>NCT00422084</DOCNO>
	<brief_summary>The purpose study compare efficacy safety fix combination pyronaridine artesunate ( 180:60 mg ) Coartem® ( artemether lumefantrine ) child adult acute uncomplicated P falciparum malaria .</brief_summary>
	<brief_title>Pyronaridine Artesunate ( 3:1 ) Versus Coartem® P Falciparum Malaria Patients</brief_title>
	<detailed_description>Artemisinin-based combination therapy ( ACTs ) consider today WHO best anti-malarials term efficacy low propensity resistance . Pyronaridine artesunate new ACT development treat acute uncomplicated malaria . Pyronaridine artesunate antimalarial agent history clinical use separately combination drug . Each drug powerful anti-schizonticidal action . The aim fix dose combination pyronaridine artesunate treatment uncomplicated acute malaria provide rapid reduction parasitemia once-daily three-day regimen , thereby improve compliance reduce risk recrudescence slow elimination pyronaridine .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Lumefantrine</mesh_term>
	<mesh_term>Artemether</mesh_term>
	<mesh_term>Artemether-lumefantrine combination</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Pyronaridine</mesh_term>
	<criteria>Male female patient age 3 60 year , inclusive . Body weight 20 kg 90 kg clinical evidence severe malnutrition . Presence acute uncomplicated P. falciparum monoinfection confirm : 1 . Fever , define axillary/tympanic temperature ≥ 37.5°C oral/rectal temperature ≥ 38°C , document history fever previous 24 hour , 2 . Positive microscopy P. falciparum parasite density 1,000 100,000 asexual parasite count/μl blood . Written informed consent , accordance local practice , provide patient and/or parent/guardian/spouse . Ability swallow oral medication . Patients sign symptom severe/complicated malaria require parenteral treatment accord World Health Organization Criteria 2000 . Mixed Plasmodium infection . Severe vomit severe diarrhoea . Known history evidence clinically significant disorder . Presence significant anaemia , define Hb &lt; 8 g/dL . Presence febrile condition cause disease malaria Known history hypersensitivity , allergic adverse reaction pyronaridine , lumefantrine artesunate artemisinins . Patients known disturbance electrolytes balance , e.g. , hypokalaemia hypomagnesaemia . Use antimalarial agent within 2 week prior start study evidence positive urine test . Female patient childbearing potential must neither pregnant ( demonstrated negative pregnancy test ) lactating , must willing take measure become pregnant study period . Patients take drug metabolise cytochrome enzyme CYP2D6 ( flecainide , metoprol , imipramine , amitriptyline , clomipramine ) . Received investigational drug within past 4 week . Known active Hepatitis A IgM ( HAVIgM ) , Hepatitis B surface antigen . ( HBsAg ) Hepatitis C antibody ( HCV Ab ) . Known seropositive HIV antibody . Liver function test [ ASAT/ALAT level ] 2.5 time upper limit normal range . Known significant renal impairment indicate serum creatinine 1.4 mg/dL .</criteria>
	<gender>All</gender>
	<minimum_age>3 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2008</verification_date>
	<keyword>Malaria</keyword>
	<keyword>ACT</keyword>
	<keyword>P falciparum</keyword>
</DOC>